New York, NY – According to filings with the U.S. Securities and Exchange Commission, Delcath Systems is raising $20,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Jennifer Simpson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company’s principal focus is on the treatment of primary and metastatic liver cancers.

To learn more about Delcath Systems, visit http://delcath.com/

Contact:
Jennifer Simpson, Chief Executive Officer
212-489-2100
jsimpson@delcath.com
https://www.linkedin.com/in/jennifer-simpson-07a30b17/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved